Ensemble Therapeutics and Novartis will collaborate in the development of Ensemble's investigational inhibitors of the interleukin-17 protein, a target for several autoimmune disorders. The firms also will use Ensemble's drug discovery technology to co-develop small molecule drugs against targets chosen by Novartis. The deal includes upfront and milestone fees plus sales royalties.

Full Story:
PharmaTimes (U.K.)

Related Summaries